MRC Collaborate with the Functional Genomics Screening Laboratory

Funding available to support academic researchers to collaborate with the functional genomics screening laboratory (FGSL) on projects using complex human in vitro models for CRISPR screening to better understand model biology and enable target identification.

This opportunity from the Medical Research Council (MRC) enables applicants to collaborate with the functional genomics screening laboratory (FGSL) on projects using complex human in vitro models for CRISPR screening to better understand model biology and enable target identification.

The FGSL is a joint venture between MRC, AstraZeneca and the Milner Therapeutics Institute, University of Cambridge. It has been set up to enable UK-based academic groups (and where space allows UK based small medium enterprises and industry) to have access to a state-of-the-art arrayed functional genomics screening laboratory.

All projects will be highly collaborative. Applicants will define the purpose of the screen and the desired outcomes. Screens will be carried out by scientists employed at Milner Therapeutics Institute (MTI). However, all screens will be run as collaborations to ensure the best possible outcome and data.

Input from the proposing lead applicant will be key to understand:

• The model.
• The screen of interest.
• Likely endpoint assays.